S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ATOS Atossa Therapeutics Inc

0.9897

0.0456 (4.83%)

Jan 02 2025 - Closed

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics Inc News

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Thursday 12 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Wednesday 11 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 10 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Tuesday 10 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Monday 9 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Thursday 21 November 2024 (1 month ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Wednesday 20 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Tuesday 12 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

More Atossa Therapeutics Inc News Articles

Bmo Income Etf Portfolio...

BFCM Banque Federative C...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions